Baillie Gifford reports 4.93% Ginkgo Bioworks (DNA) stake in 13G/A
Rhea-AI Filing Summary
Ginkgo Bioworks Holdings, Inc. (DNA) received an amended Schedule 13G/A from Baillie Gifford & Co, a Scotland-based investment adviser, reporting its ownership in the company’s Class A common stock as of 12/31/2025.
Baillie Gifford reports beneficial ownership of 2,391,649 Class A shares, representing 4.93% of the class. It has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ginkgo Bioworks.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake does Baillie Gifford hold in Ginkgo Bioworks (DNA)?
Baillie Gifford & Co reports beneficial ownership of 2,391,649 shares of Ginkgo Bioworks Class A common stock, representing 4.93% of the class. This ownership is reported as of December 31, 2025 in an amended Schedule 13G/A filing.
What type of filing is this for Ginkgo Bioworks (DNA)?
This is an amended Schedule 13G/A, which reports significant share ownership in Ginkgo Bioworks by Baillie Gifford & Co. Schedule 13G is used for passive holders who are not seeking to change or influence control of the company.
Is Baillie Gifford trying to influence control of Ginkgo Bioworks?
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Ginkgo Bioworks. It characterizes Baillie Gifford as a passive investment adviser holder.
Why does Baillie Gifford’s Ginkgo Bioworks filing mention 5 percent or less?
Item 5 notes ownership of 5 percent or less of the class, consistent with the reported 4.93% stake. This indicates Baillie Gifford’s holdings are below the 5% threshold that often signifies a larger, more influential position in U.S. securities reporting.